100% of patients get objective relief, and the latest clinical results of ready-to-use natural killer cell therapy are positive

On November 22, 2021, Affimed announced that its umbilical cord blood-derived natural killer cell therapy will be combined with the innate cell engager (ICE) AFM13 in advance to treat Hodgkins and patients who have received multi-line pre-treatment.

Natural killer (NK) cells are the innate immune cells that exist in the human body.

Affimed's strategy is to combine natural killer cells that have no targeting ability with the innate cell adaptor that gives them the ability to target

▲The mode of action of the combination of innate cell binders and NK cells (picture source: Affimed official website)

As of October 31, 2021, a total of 18 patients with CD30-positive relapsed/refractory Hodgkin’s lymphoma (n=16) and non-Hodgkin’s lymphoma (n=2) received different doses of this innovative treatment Treatment

The results of the trial showed that of the 18 patients, 16 patients achieved objective remissions, including 7 complete remissions (CR) and 9 partial remissions (PR)

In terms of safety, the treatment combination showed good tolerance

Reference materials:

[1]AffimedAnnounces100%ObjectiveResponseRateatHighestDoseinPhase1-2StudyofCordBlood-derivedNaturalKillerCellsPre-complexedwithInnateCellEngagerAFM13forCD30-positiveLymphomas.

(The original text has been deleted)